Prognostic value of early assessment by ⁶⁸Ga-DOTATATE PET/CT for the treatment of well-differentiated grade 2 gastroenteropancreatic neuroendocrine tumors with ¹⁷⁷Lutetium-oxodotreotide.”

Condition studied

Gastroenteropancreatic neuroendocrine tumors

Investigational medicinal product(s)

Eligibility

Primary endpoint

Progression-free survival is defined as the time from the first injection of ¹⁷⁷Lu-oxodotreotide to the occurrence of the first documented tumor progression according to RECIST 1.1 criteria during CT follow-up.

Endpoint detail

Progression-free survival is defined as the time from the first injection of ¹⁷⁷Lu-oxodotreotide to the occurrence of the first documented tumor progression according to RECIST 1.1 criteria during CT follow-up. Tumor assessment is performed every 3 months after treatment initiation using CT and RECIST 1.1 criteria. ⁶⁸Ga-edotreotide PET/CT images acquired immediately before the third injection of ¹⁷⁷Lu-oxodotreotide will be independently analyzed